Advancing a Hepatitis C vaccine candidate to human trials by developing a production cell line, standardising manufacturing protocols, and optimising the vaccine regimen. Preclinical studies show that the vaccine targets conserved neutralising epitopes, potentially inducing broadly neutralising antibodies.